The European Commission has approved dimethyl fumarate (Tecfidera, Biogen Idec) as a first-line oral treatment in relapsing-remitting multiple sclerosis (MS), the company reported today. Dimethyl ...
WASHINGTON (Reuters) - U.S. regulators on Wednesday approved a new multiple sclerosis drug made by Biogen Idec Inc that is widely expected to become the No. 1 oral treatment for the disease, with ...
The FINANCIAL — Biogen unveiled new TECFIDERA (dimethyl fumarate) research that reinforces its strong and sustained efficacy in newly diagnosed relapsing-remitting multiple sclerosis (RRMS) patients ...
Generic Tecfidera is a treatment for patients with relapsing forms of multiple sclerosis, while generic Vimpat is used as monotherapy or adjunctive therapy in patients with partial onset seizures.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback